医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Qurient Announces Positive Phase 2a Data of Novel Antibiotic for the Treatment of Tuberculosis

2019年06月03日 PM10:00
このエントリーをはてなブックマークに追加


 

SEONGNAM-SI, South Korea

Qurient Co. Ltd. today announced positive results from the Phase 2a EBA (early bactericidal activity) clinical trial for telacebec (Q203), a first-in-class, orally-available antibiotic for the treatment of tuberculosis (TB). Telacebec is a selective inhibitor with high specificity for the cytochrome bc1 complex of Mycobacterium tuberculosis. This complex is a critical component of the electron transport chain, and inhibition disrupts the bacterium’s ability to generate energy.

The EBA trial assessed the pharmacokinetics, safety, and activity of telacebec in three dose strength (100 mg, 200 mg and 300 mg) in the treatment of adult patients with pulmonary TB. Telacebec met the primary objective of rate of change in the time to positivity (TTP) in sputum over days 0 to 14. Telacebec was safe and well tolerated throughout the different dose strengths. Full results from EBA trial are expected to be presented at future scientific meetings.

“Telacebec has been developed in response to the urgent need for new antibiotics to treat drug-resistant tuberculosis,” said Kiyean Nam, Ph.D., CEO and CSO of Qurient. “The positive data from this trial is a significant milestone in developing an antibiotic with a novel mechanism of action that can benefit all TB patients. In addition, telacebec may have potential to treat buruli ulcer, another devastating infectious disease that is also part of the U.S. FDA’s priority review voucher program.”

Telacebec has received Orphan Drug Designation and Fast Track Designation from the U.S. FDA. Telacebec also has been found effective against buruli ulcer (Mycobacterium ulcerans), a chronic, necrotizing disease that affects skin and sometimes bone and can lead to permanent deformity and long-term disability (Nature Communications, 2018).

This trial took place in South Africa and was led by global key opinion leaders in TB located in Cape Town, South Africa. Professor Andreas Diacon, a national principal investigator at TASK Applied Science, Doctor Veronique de Jager, principal investigator at TASK Applied Science, and Professor Rodney Dawson, principal investigator at University of Cape Town Lung Institute.

Telacebec is in Phase 2a clinical development under a U.S. IND (ClinicalTrials.gov: NCT03563599).

About Qurient

Qurient is a clinical-stage biopharmaceutical company listed in Korea Exchange (KRX 115180). Qurient has two programs in clinical development and one program in the IND enabling stage. Q301 is a topical leukotriene inhibitor for atopic dermatitis in a Phase 2b clinical trial in the United States. Q702 is a Axl/Mer/CSF1R triple inhibitor for immune-oncology and drug resistant non-small cell lung cancer, licensed from Max Planck Innovation and Lead Discovery Center in Germany. Telacebec (Q203), which just completed Phase 2a clinical trial, was licensed from Institute of Pasteur in Korea. For more info, please visit www.qurient.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190603005166/en/

CONTACT

Jessica Yingling, Ph.D., Little
Dog Communications Inc.
, jessica@litldog.com,
+1.858.344.8091

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作